Catechol O-methyltransferase (COMT) catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to catechol substrates such as the neurotransmitters dopamine, epinephrine, and norepinephrine. This O-methylation results in one of the main degradative pathways of the catecholamine transmitters. COMT is located in the postsynaptic neuron and is involved in the metabolism of catechol estrogen drugs used in the treatment of hypertension, asthma, Parkinson’s disease and the inactivation of catecholamine neurotransmitters through enzymatic degradation. COMT appears in tissues in 2 forms, a soluble form and a membrane-bound form which differ in their N-termini. COMT inhibitors prevent L-DOPA degradation, increase its availability and are used in the treatment of patients with Parkinson’s disease.

COMT Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 221 amino acids (51-271 a.a.) and having a molecular mass of 24.4 kDa. It is purified by proprietary chromatographic techniques. Purity is greater than 95.0% as determined by SDS-PAGE. COMT protein is provided in 20mM Tris-buffer, pH-8, 1mM MgCl2 and 10% Glycerol.

Amino Acid Sequence:

MGDTKEQRIL NHVLQHAEPG NAQSVLEAID TYCEQKEWAM NVGDKKGKIV DAVIQEHQPS VLLELGAYCG YSAVRMARLL SPGARLITIE INPDCAAITQ RMVDFAGVKD KVTLVVGASQ DIIPQLKKKY DVDTLDMVFL DHWKDRYLPD TLLLEECGLL RKGTVLLADN VICPGAPDFL AHVRGSSCFE CTHYQSFLEY REVVDGLEKA IYKGPGSEAG P

To view protocol(s) for this and other products please visit: www.ATSbio.com/support/protocols

Advanced Targeting Systems(ATS)位于美国加州圣地亚哥， 成立于1994年。 公司发起人Douglas Lappi和Ronald Wiley博士在实验室开发出先进的分子神经外科学研究技术。ATS主要生产用于科研和药物研发的靶向试剂，公司在疼痛和药物转运的研究及临床治疗的两个产品已获专利保护。目前，产品包括靶向毒素 (可提供基底前脑胆碱能神经元、去甲肾上腺素能和肾上腺素能神经元、巨噬细胞和小胶质细胞的特异性损伤试剂等)、二抗生物素、神经元抗体、神经递质抗体、蛋白质和荧光结合物、免疫毒素对照等。